# A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

> **NCT00531453** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 98 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib, dexamethasone, and thalidomide
- **DRUG:** bortezomib, dexamethasone, thalidomide, and cyclophosphamide

## Key facts

- **NCT ID:** NCT00531453
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2012-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531453, "A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00531453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*